Market Overview

UPDATE: Cantor Fitzgerald Initiates Buy, $43 on Walgreen Post Express Scripts Contract Resolution

Share:
Related WAG
IPO Outlook: API-Focused Software Tech Company Apigee Is A Silent Growth Story
Jana Partners' Barry Rosenstein: 'The Walgreens Situation Is Terrific'

Cantor Fitzgerald initiated its coverage on Walgreen (NYSE: WAG) with a Buy rating and a price target of $43.

Cantor Fitzgerald noted, "We expect 50% recovery of the lost script volume by FY:13. The combination of synergies from Alliance Boots, impact from generics, contribution from the USA Drug acquisition, and the benefits of an aging store fleet should be accretive by close to $0.30 per share in FY:13. We prefer to be conservative in our assumptions for ESRX and assume that marketing expenses are likely to offset $0.11-$0.12 per share benefit from recaptured ESRX scripts in FY:13. If customer re-activation costs are lower than our expectations, or if Walgreen's is able to recapture a higher portion of ESRX customers relative to our assumption, we see potential for further upside.."

Walgreen closed at $35.44 on Tuesday.

Latest Ratings for WAG

DateFirmActionFromTo
Dec 2014BarclaysMaintainsEqual-weight
Dec 2014JP MorganMaintainsOverweight
Dec 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for WAG
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (WAG)

Around the Web, We're Loving...